
PRA Health Sciences, Inc. EBITDA 2011-2026 | PRAH
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA PRA Health Sciences, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| 416 M | 482 M | 429 M | 343 M | 277 M | 243 M | 153 M | - | 77.9 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 482 M | 77.9 M | 303 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Diagnostics research industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
-46 M | - | -6.23 % | $ 30.6 M | ||
|
Heska Corporation
HSKA
|
-6.33 M | - | - | $ 1.31 B | ||
|
Fulgent Genetics
FLGT
|
-67 M | $ 17.11 | -1.55 % | $ 527 M | ||
|
Agilent Technologies
A
|
1.67 B | $ 114.96 | 0.15 % | $ 34.9 B | ||
|
ICON Public Limited Company
ICLR
|
1.59 B | $ 116.78 | 0.18 % | $ 9.63 B | ||
|
Celcuity
CELC
|
-172 M | $ 138.23 | -3.02 % | $ 6.46 B | ||
|
Akumin
AKU
|
70.1 M | - | -17.87 % | $ 25.9 M | ||
|
Illumina
ILMN
|
-479 M | $ 144.41 | -0.29 % | $ 23 B | ||
|
Co-Diagnostics
CODX
|
-49.1 M | $ 5.07 | 36.66 % | $ 6.74 M | ||
|
Castle Biosciences
CSTL
|
-2.04 M | $ 20.15 | -1.9 % | $ 584 M | ||
|
Aspira Women's Health
AWH
|
-7.8 M | - | -6.19 % | $ 10.5 M | ||
|
Accelerate Diagnostics
AXDX
|
-33.9 M | - | -61.36 % | $ 2.46 M | ||
|
Biocept
BIOC
|
-30.3 M | - | -13.05 % | $ 7.29 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
-3.26 M | - | - | $ 562 M | ||
|
Guardant Health
GH
|
-398 M | $ 118.95 | 0.8 % | $ 14.9 B | ||
|
CareDx, Inc
CDNA
|
-15.8 M | $ 21.63 | 0.28 % | $ 1.15 B | ||
|
Chembio Diagnostics
CEMI
|
-21.1 M | - | 0.22 % | $ 16.8 M | ||
|
Check-Cap Ltd.
CHEK
|
-2.37 M | - | - | $ 9.42 M | ||
|
HTG Molecular Diagnostics
HTGM
|
-20.2 M | - | -20.0 % | $ 1.06 M | ||
|
Interpace Biosciences
IDXG
|
4.51 M | $ 1.82 | 1.11 % | $ 8.05 M | ||
|
Lantheus Holdings
LNTH
|
381 M | $ 103.0 | 9.03 % | $ 6.95 B | ||
|
Global Cord Blood Corporation
CO
|
652 M | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
-35.1 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
-6 M | - | - | $ 7.1 B | ||
|
Mettler-Toledo International
MTD
|
51.1 M | $ 1 103.09 | 1.16 % | $ 22.7 B | ||
|
Genetron Holdings Limited
GTH
|
-518 M | - | 0.12 % | $ 80.1 M | ||
|
NeoGenomics
NEO
|
-79.8 M | $ 9.23 | 1.32 % | $ 1.18 B | ||
|
DermTech
DMTK
|
-104 M | - | -11.32 % | $ 2.94 M | ||
|
National Research Corporation
NRC
|
30.2 M | $ 19.08 | 0.21 % | $ 427 M | ||
|
Charles River Laboratories International
CRL
|
428 M | $ 160.3 | 0.91 % | $ 7.95 B | ||
|
Enzo Biochem
ENZ
|
-11.1 M | - | -8.98 % | $ 14.8 K | ||
|
Medpace Holdings
MEDP
|
562 M | $ 432.8 | 0.63 % | $ 12.5 B | ||
|
Natera
NTRA
|
-524 M | $ 203.19 | -0.25 % | $ 20 B | ||
|
Exact Sciences Corporation
EXAS
|
-81.4 M | - | - | $ 19.8 B | ||
|
Myriad Genetics
MYGN
|
-334 M | $ 3.82 | -2.3 % | $ 354 M | ||
|
Personalis
PSNL
|
-78 M | $ 8.47 | 2.67 % | $ 756 M | ||
|
Koninklijke Philips N.V.
PHG
|
2.55 B | $ 26.95 | -0.74 % | $ 25.6 B | ||
|
Senseonics Holdings
SENS
|
-66.8 M | $ 6.34 | 2.92 % | $ 265 M | ||
|
QIAGEN N.V.
QGEN
|
660 M | - | - | $ 10.6 B | ||
|
Soleno Therapeutics
SLNO
|
11.4 M | - | - | $ 2.69 B | ||
|
Biomerica
BMRA
|
-5.05 M | $ 2.49 | 2.05 % | $ 5.72 M | ||
|
Twist Bioscience Corporation
TWST
|
-111 M | $ 60.57 | 2.95 % | $ 3.62 B | ||
|
Laboratory Corporation of America Holdings
LH
|
2.07 B | $ 259.93 | 1.63 % | $ 21.6 B | ||
|
Thermo Fisher Scientific
TMO
|
8.8 B | $ 448.28 | -0.24 % | $ 169 B | ||
|
Trinity Biotech plc
TRIB
|
-21.2 M | $ 0.6 | -3.7 % | $ 216 M | ||
|
Motus GI Holdings
MOTS
|
-11.5 M | - | -34.28 % | $ 263 K | ||
|
Waters Corporation
WAT
|
359 M | $ 342.37 | 0.4 % | $ 20.4 B | ||
|
Neogen Corporation
NEOG
|
-942 M | $ 8.9 | 0.45 % | $ 1.93 B | ||
|
Quest Diagnostics Incorporated
DGX
|
2.13 B | $ 195.21 | 0.72 % | $ 21.7 B |